Related Experiment Video

Updated: Jun 4, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Time to rethink clinically important outcomes in platelet transfusion trials

Nancy M Heddle1, Donald M Arnold, Kathryn E Webert

  • 1Department of Medicine, McMaster University, Hamilton, Ontario, Canada. heddlen@mcmaster.ca

Transfusion
|February 12, 2011
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 4, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Articles linked to this work by shared authors, journal, and citation graph.

American Society of Hematology 2026 Guidelines for Immune Thrombocytopenia (ITP): Initial and Second-Line Therapy in Adults with Primary ITP.

Blood advances·2026

Acute heparin-induced thrombocytopenia following aortic dissection repair with platelet count recovery and anti-platelet factor 4/heparin antibody seroreversion despite ongoing device-related heparin exposure.

Haematologica·2026

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I-WISh) 2.0.

American journal of hematology·2026

Engineering single-chain variable fragments to identify pathogenic antibodies in heparin-induced thrombocytopenia.

Blood·2026

Red blood cell transfusion thresholds in acute leukemia: Current practice and physician perspectives from a national survey.

Transfusion·2026

Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia.

Blood advances·2026

The lymphocyte function of allogeneic peripheral blood stem cell grafts is associated with relapse and cytomegalovirus reactivation.

Transfusion·2026

Massive fetomaternal hemorrhage and successful prevention of maternal RhD alloimmunization: A case report.

Transfusion·2026

Blood donation practices and perceptions among men who have sex with men in China: A nationwide mixed-methods study.

Transfusion·2026

Three novel RHD variant alleles were identified through routine molecular screening of serologically RH1 negative first-time blood donors.

Transfusion·2026

The blood system in Ukraine: Experience in martial law conditions.

Transfusion·2026

Relevance of circulating IgG levels as a marker of health in plasma donors.

Transfusion·2026

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

Blood·2026

Utility of multiparametric flow cytometry in the diagnosis and staging of Classic Hodgkin lymphoma-Experience in real-world practice.

Cytometry. Part B, Clinical cytometry·2026

Genetic thrombophilia in cancer-associated thrombosis: the fly plowing with the ox or an old player's new role?

Haematologica·2026

Making remissions last: the promise of maintenance in primary central nervous system lymphoma.

Haematologica·2026

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Haematologica·2026

The many faces (and phenotypes) of BCR::ABL1-driven acute leukemia.

Haematologica·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us